https://www.selleckchem.com/pr....oducts/beta-lapachon
In-hospital mortality of redo AVI was 7.6% (5.3% for redo TAVR or BAV vs. 13.8% for redo SAVR, unadjusted p=0.1. Stroke, myocardial infarction, bleeding requiring transfusion, new pacemaker, and acute kidney injury rates were 4.7%, 2.6%, 9.3%, 10.0%, and 31.2%, respectively in redo AVI. Length of stay and hospital cost was 4.8days and 55,826U.S. dollars, respectively. The incidence of redo AVI was low following TAVR but was associated with high mortality and morbidities. The incidence of redo AVI was low following TAVR but was
Like
Comment
Share
